Hagiwara Yoko, Ogawa Satoshi
Cardio-pulmonary Division, Keio University School of Medicine.
Nihon Rinsho. 2002 Jul;60(7):1278-85.
Recentry, therapies for arrhythmias have been extremely advanced by accumulation of electrophysiological knowledge, improvement of diagnostic technique, and development of antiarrhythmic drugs and devices(pacemakers, catheter ablation and implantable cardioverter-defibrillators). After the report of the CAST(Cardiac Arrhythmia Suppression Trial), the Sicilian Gambit was presented as new strategies of drug therapy. Now in the United States, three AHA guidelines were published. Besides in Japan 'the guidelines for antiarrhythmic drugs' based on the Sicilian Gambit was published. 'The guidelines for management of Atrial fibrillation' and 'the guidelines for antiarrhythmic devices' were also reported. Here, these guidelines are reviewed.
近年来,随着电生理知识的积累、诊断技术的改进以及抗心律失常药物和器械(起搏器、导管消融术和植入式心脏复律除颤器)的发展,心律失常的治疗取得了极大进展。在心脏心律失常抑制试验(CAST)报告之后,西西里策略作为药物治疗的新策略被提出。目前在美国,发布了三项美国心脏协会(AHA)指南。此外,在日本,基于西西里策略的“抗心律失常药物指南”也已发布。还报道了“心房颤动管理指南”和“抗心律失常器械指南”。在此,对这些指南进行综述。